A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase II trial show.
Science Brief thanks to EurekAlert.
Read more here:
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
Net News Publisher for Science News
Related articles
- Adult Lung Stem Cells, Vital to Injury Repair, Associated with Poor Cancer Prognosis (netnewspublisher.com)
- ‘Synthetic Lethality’ Strategy Improves Molecularly Targeted Cancer Therapy (netnewspublisher.com)
- New Investigational Compound Targets Pancreatic Cancer Cells (netnewspublisher.com)
